Michael Higgins

Michael J.
Higgins is currently Chief Executive Officer & Director at KinDex Pharmaceuticals, Inc. since 2015.
He serves as Chairman at Voyager Therapeutics, Inc. since 2022 and at Pulmatrix, Inc. since 2020.
He is Director at Morgan Stanley Private Equity Access Fund II LP, Sea Pharmaceuticals LLC since 2016, Madauder Therapeutics, Inc. since 2016, Private Equity Access Fund II, and Independent Director at Cyclerion Therapeutics, Inc. since 2023 and Nocion Therapeutics, Inc. since 2020.
Former roles include Director at Pulmatrix Operating Co., Inc. in 2015, Microbia, Inc., Ruthigen, Inc., Independent Director at Genocea Biosciences, Inc. from 2015 to 2022, Independent Director at CAMP4 Therapeutics Corp.
from 2017 to 2026, VP-Corporate Finance & Business Development at Genzyme Corp.
from 1997 to 2003, Chief Operating Officer at Ironwood Pharmaceuticals, Inc. in 2014, Chief Financial Officer at Procept, Inc. from 1992 to 1997, and Chief Financial Officer at Boston Business Journal.
Education includes undergraduate studies at Cornell University and an MBA from Tuck School of Business at Dartmouth.